Skip to content
CancerIndex

Loading the knowledge graph…

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — knowledge graph · CancerIndex